Authors
Latest:
Dr Yap on Saruparib in BRCA1/2+, PALB2+, or RAD51C/D+ Advanced Solid TumorsTimothy Yap, MBBS, PhD, FRCP, discusses data for saruparib in harboring BRCA1/2, PALB2, or RAD51C/D mutations.
Latest:
Dr. Tykodi on the KEYNOTE-427 Trial With Pembrolizumab in RCCScott S. Tykodi, MD, PhD, provides background to the phase 2 KEYNOTE-427 trial with pembrolizumab in renal cell carcinoma.
Latest:
Window of Opportunity Trials Are Needed for Novel Tissue Biomarker Analysis in Head and Neck CancersDrug development is a difficult and ever-changing process, with new agents being developed by industry and academic partners.
Latest:
Future Perspectives in Higher-Risk MDSDr Gustavo Rivero comments on novel treatment combinations and potential new biomarkers in patients with MDS.
Latest:
Dr Hogen on Survival Outcomes With Neoadjuvant Chemotherapy and ICS in Epithelial Ovarian CancerLiat Hogen, MD, FRCSC, discusses the survival outcomes achieved with interval cytoreductive surgery following neoadjuvant chemotherapy in a study of patients with initial unresectable stage IV ovarian cancer.
Latest:
Dr Nakamura on the Association Between MRD Negativity and DFS in Resected CRCYoshiaki Nakamura, MD, PhD, discusses updated findings from an analysis of the association between circulating tumor DNA minimal residual disease status and disease-free survival in the GALAXY trial, an observational arm of the ongoing CIRCULATE-Japan trial in patients with resected colorectal cancer.
Latest:
Dr. Alistar on the Need to Develop Biomarkers in Pancreatic CancerAngela Tatiana Alistar, MD, discusses the need to develop biomarkers in pancreatic cancer.
Latest:
Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR TumorsDrs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
Latest:
Unmet Needs in SM TreatmentThe panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.
Latest:
LAG-3 Fills a Complex Role in the Immune SystemThe LAG-3 pathway has emerged as the next target for the use of immune checkpoint inhibitors in oncology.
Latest:
Key Takeaways: Advancements and Challenges in Kidney Cancer TreatmentLeading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.
Latest:
Dr Koehne on the Use of Chemotherapy-Only Conditioning Regimens in Hematologic MalignanciesGuenther Koehne, MD, PhD, discusses the use of chemotherapy-only conditioning regimens for patients with hematologic malignancies undergoing transplant.
Latest:
Dr. Robesti on Optimizing Patient Selection for Salvage Lymph Node Dissection in Prostate CancerDaniele Robesti, MD, discusses how to optimize patient selection for salvage lymph node dissection in prostate cancer.
Latest:
Dr. Spiess on Key Updates in the Management of Penile CancerPhilippe E. Spiess, MD, MS, FACS, shares key updates in the management of patients with penile cancer.
Latest:
Dr Melenhorst on the Evolving Understanding of CAR T-Cell Therapies in CLLJan Joseph Melenhorst, PhD, discusses the evolving understanding of the use of CAR T-cell therapies in the treatment of patients with chronic lymphocytic leukemia.
Latest:
BTK Degraders and Other Targets in Mantle Cell LymphomaExperts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.
Latest:
Dr. Efstathiou on the rPFS Benefit Achieved With Apalutamide Regimen in mCRPCEleni Efstathiou, MD, discusses the key findings of the placebo-controlled, double-blind phase 3 ACIS study of apalutamide and abiraterone acetate plus prednisone versus prednisone alone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.
Latest:
PARP Inhibitor Therapy Options Are Transforming Landscape in Ovarian CancerPARP inhibitors have fundamentally changed our therapeutic algorithms in ovarian cancer, even as their use continues to evolve.
Latest:
Dr Villalona-Calero on the Investigation of KB-0742 in Relapsed/Refractory Solid TumorsMiguel Villalona-Calero, MD, discusses interim data from a phase 1/2 investigation of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma and highlights the ongoing evaluation of the agent’s safety.
Latest:
Dr. Angiolillo on the Toxicity Profile of Traditional Treatment in Pediatric B-ALLAnne Angiolillo, MD, discusses the adverse effects that are associated with traditional treatment in pediatric B-cell acute lymphoblastic leukemia.
Latest:
Dr. Olopade on Racial Disparities in Breast Cancer OutcomesOlufunmilayo Falusi Olopade, MD, FACP, discusses racial disparities in breast cancer outcomes.
Latest:
Dr Allan on the Investigation of Obinutuzumab Triplet Consolidation in MRD-Positive CLLJohn N. Allan, MD, discusses a planned evaluation of obinutuzumab triplet consolidation therapy for patients with chronic lymphocytic leukemia /small lymphocytic lymphoma who remain minimal residual disease–positive after initial treatment with zanubrutinib and venetoclax .
Latest:
Dr Kambhampati on the Rationale For Evaluating Real-World Outcomes With Brexu-Cel in MCLSwetha Kambhampati, MD, discusses the rationale for evaluating outcomes with in a subgroup anlaysis of patients with relapsed/refractory mantle cell lymphoma, and how prior data from the phase 3 ZUMA-2 study supported the inception of this trial.
Latest:
Jumping Genes in Cancer Cells Open Door to New ImmunotherapiesResearch from Washington University School of Medicine in St. Louis suggests that transposable elements in various cancers potentially may be used to direct novel immunotherapies to tumors that don’t typically respond to immune-based treatments.
Latest:
Dr Ball on Data From from the IMerge Trial in Low– to Intermediate-Risk MDSSomedeb Ball, MBBS, discusses data from the phase 3 IMerge trial of imetelstat vs placebo in low– to intermediate-risk myelodysplastic syndromes.
Latest:
Exciting NSCLC Data Updates from ESMO 2022The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.
Latest:
Location Matters: US Patients With Adult T-Cell Leukemia/Lymphoma Have Distinct Clinical, Genetic FeaturesAdult T-cell leukemia/lymphoma is a rare and very aggressive T-cell neoplasm with an extremely poor prognosis. It is also the only human cancer caused by a retrovirus—human T-cell leukemia virus.
Latest:
Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces RelapseA targeted therapy for children with high-risk Hodgkin lymphoma was shown to significantly reduce relapse rates when tested in a clinical trial conducted by the Children’s Oncology Group and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children’s Healthcare of Atlanta and Winship Cancer Institute of Emory University.
